EMCURE PHARMA UK LTD
Get an alert when EMCURE PHARMA UK LTD files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£236K
+175.6% highest in 3 filed years
Net assets
£49M
+0.7% highest in 3 filed years
Employees
4
0% vs 2025
Profit before tax
£420K
+1,131.2% first positive since 2025
Net assets
3-year trend · vs Consumer Discretionary median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2026-03-31
| Metric | Trend | 2024-03-31 | 2025-03-31 | 2026-03-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £404,335 | £0 | — | — | |
| Operating profit | -£349,338 | -£62,200 | £402,258 | +746.7% | |
| Profit before tax | £13,822,421 | -£40,737 | £420,093 | +1,131.2% | |
| Net profit | £13,822,421 | -£40,737 | £315,070 | +873.4% | |
| Cash | £128,564 | £85,747 | £236,320 | +175.6% | |
| Total assets less current liabilities | £52,356,299 | £52,315,562 | £48,780,809 | -6.8% | |
| Net assets | £48,506,476 | £48,465,739 | £48,780,809 | +0.7% | |
| Equity | £48,506,476 | £48,465,739 | £48,780,809 | +0.7% | |
| Average employees | 4 | 4 | 4 | 0% | |
| Wages | — | — | — | — | |
| Directors' remuneration | — | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|
| Operating margin | -86.4% | — | — | |
| Return on capital employed | -0.7% | -0.1% | 0.8% | |
| Gearing (liabilities / total assets) | — | 10.1% | 10.6% | |
| Current ratio | 5.15x | 7.31x | 2.09x | |
| Interest cover | -0.57x | -0.22x | 1.44x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- MHA Chartered Accountants & Statutory Auditor
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Based on these assessments and having regard to the resources available to the Company, the Directors have concluded that there is no material uncertainty and that they can continue to adopt the going concern basis in preparing the financial statements.”
Group structure
- EMCURE PHARMA UK LTD · parent
- Tillomed Laboratories Limited 100%
- Tillomed Pharma GmbH 100%
- Laboratorios Tillomed Spain SLU 100%
- Tillomed Italia S.R.L. 100%
- Tillomed France SAS 100%
- Emcure Pharma Peru SAC 100%
- Tillomed Malta Ltd 100%
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 14 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| MEHTA, Samit Satish | Director | 2018-05-09 | Apr 1980 | Indian |
| SHAIKH, Tajuddin | Director | 2016-11-18 | May 1974 | Indian |
| SRIMAL, Ajit Chand | Director | 2025-01-27 | Aug 1958 | British |
Show 14 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BAER, Rudolf Thomas | Director | 2024-03-31 | 2025-01-14 |
| BASHYAM, Renganathan | Director | 2021-07-20 | 2023-03-30 |
| BERZIGOTTI, Massimo | Director | 2021-06-03 | 2024-03-31 |
| CAMA, Zarir Jal | Director | 2018-05-09 | 2019-05-14 |
| DIXIT, Vineet Kumar | Director | 2016-11-18 | 2018-05-09 |
| GINAI, Musharaf Mahmood Ahmed | Director | 2014-09-09 | 2015-03-16 |
| JAIN, Hitesh Sohanlal | Director | 2021-07-20 | 2025-04-16 |
| MARTH, William Steven | Director | 2018-05-09 | 2021-07-01 |
| MEHTA, Samit Satish | Director | 2014-09-09 | 2016-11-18 |
| RANADE, Mukund Pandurang | Director | 2012-11-06 | 2015-02-11 |
| SRIMAL, Ajit Chand | Director | 2021-07-20 | 2021-08-26 |
| SRIMAL, Ajit Chand | Director | 2017-07-20 | 2020-03-31 |
| THAPAR, Vikas | Director | 2012-11-06 | 2016-11-25 |
| WALTER, Ian Alan | Director | 2014-09-09 | 2017-06-27 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Emcure Pharmaceuticals Limited | Corporate entity | Shares 75–100% | 2016-04-06 | Ceased 2016-04-06 |
Filing timeline
Last 20 of 90 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-05-18 | AA | accounts | Accounts with accounts type full | |
| 2026-02-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-07-14 | AA | accounts | Accounts with accounts type full | |
| 2025-06-19 | TM01 | officers | Termination director company with name termination date | |
| 2025-04-19 | DISS40 | gazette | Gazette filings brought up to date | |
| 2025-04-17 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-04-15 | GAZ1 | gazette | Gazette notice compulsory | |
| 2025-02-26 | TM01 | officers | Termination director company with name termination date | |
| 2025-02-26 | AP01 | officers | Appoint person director company with name date | |
| 2024-10-23 | AA | accounts | Accounts with accounts type full | |
| 2024-04-08 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-08 | TM01 | officers | Termination director company with name termination date | |
| 2024-03-12 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-10-24 | AA | accounts | Accounts with accounts type full | |
| 2023-08-15 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2023-08-15 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2023-04-17 | TM01 | officers | Termination director company with name termination date | |
| 2023-02-01 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2022-08-10 | AA | accounts | Accounts with accounts type full | |
| 2022-01-27 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.